This is my first post here. Couple of observations. Wait for the subgroup analysis, these results do not make sense and partly its because the sites were dispersed over US and EU and they included NYHA Class two patients who rarely go to the hospital as they are less sick. Mydicar has a different mode of action for AV fistula maturation which is a huge unmet need. As per last CC they were planning phase two trials this year for this indication. Those trials are not very expensive and if memory serves right should not take more than three months.
Idiots on parade. Interesting.
WRB, this is a line used by Monkey brains aka munkus. Instead of accusing others of multiple aliases look at yourself. Take your own advice and have no more children. One of you is enough entertainment.
You are right SPHs is not the same; its a piece of garbage compared to NYMX. The company has diluted so many times and even changed its name to hide its past.
My post was about the BPH indication being dormant. If and when prostate cancer trial begins NYMX will be doing a phase three pivotal trail while SPHS will start with a proof of concept trial AKA phase two and will be behind NYMX.
So today after the Recordati announcement NX1207 for BPH is finally laid to rest. The company keeps on hinting at a possible deal for prostate cancer based on its failed/inconclusive prostate cancer phase two trial but nothing as yet. They have been hinting at it for the last one year so I doubt its going to happen anytime soon. Sophiris is in exactly the same situation.
My sympathies and commiserations to the patient, longsuffering investors of both companies.
Thanks. I listened to it. It was not up this morning.
Apart from the trial they said they are discontinuing the development of the drug; so I guess they are handing back the European rights to Nymox.
It will be interesting to know what the results are from the trial so far if NYMOX will ever tell us.
Did you listen to the conference call, if so, can you write what was said. The slides on their website do not give any information. Thanks.
This is the guy who used to come on the NYMOX Board and rub NYMOX investors face in the mud after the NYMOX trial failed.
How does it feel to be on the other side?